Hollow nano motor with opening structure and preparation method and application thereof
Through the nanomotor with an open structure with hollow structure, the cell membrane passes through the blood-brain barrier and the built-in catalytic engine decomposes endogenous fuel, solving the problem that radiosensitizers are difficult to penetrate into the tumor center and achieving more efficient glioblastoma treatment Effect.
Patent Information
- Application Number
- CN202411252768.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art is difficult to effectively pass through the blood-brain barrier, and radiosensitizers are difficult to penetrate deep into the tumor center, resulting in poor treatment effect of glioblastoma.
A nanomotor with an open structure with hollow structure is developed, using cell membranes to pass through the blood-brain barrier, and a built-in catalytic engine to decompose endogenous fuel, promote self-driven movement, and improve the delivery efficiency and penetration depth of radiosensitizers.
Through the self-propelling mechanism of self-driven nanomotors, the delivery efficiency and penetration depth of radiosensitizers are significantly improved, the targeted effect on the tumor center is enhanced, and the therapeutic effect of glioblastoma is improved.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of new nano-biological materials, and relates to a hollow nano-motor with an opening structure and a preparation method and application thereof. Background Art
[0002] Glioblastoma (GBM) is the most common, fastest-growing, and most malignant primary brain tumor in adults. The current clinical treatment model for GBM is mainly surgical resection, supplemented by adjuvant radiotherapy (RT) and chemotherapy. Surgical treatment requires the most complete removal of tumor tissue, which is very difficult for highly invasive and heterogeneous GBM. Chemotherapy often causes severe systemic toxicity, which poses a huge challenge to patients with poor physical condition or severe organ dysfunction. Radiotherapy (RT) is a local treatment method that relies on ionizing radiation to destroy cancer cells through ionization. This non-invasive local treatment method highlights the great potential of RT for widespread application. Radiosensitizers can increase the efficiency of ionizing radiation in killing tumor cells. Despite significant progress in the development of new radiosensitizers, the treatment of GBM still faces many challenges.
[0003] First, the presence of the blood-brain barrier (BBB) prevents most radiosensitizers from entering the brain parenchyma. In addition, compared with normal tissues, the increased branching and tortuosity of blood vessels in tumors and the increased blood viscosity may hinder the delivery of blood-borne radiosensitizers. Second, the distribution of microvessels in different areas of the tumor becomes extremely uneven. The blood vessels at the front or periphery of the tumor growth tend to be highly vascularized, while the blood vessels in the center of the tumor are low vascularized and often necrotic. This not only leads to relatively high pressure in the center of the tumor, with only weak convection and diffusion, which hinders the entry of radiosensitizers into the center of the tumor, but also creates a long-term hypoxic microenvironment, making these central cells insensitive to radiation. However, the central area of GBM often contains cells with strong radioresistance, which are difficult to kill when exposed to only low doses of radiation. The above physiological barriers prevent most radiosensitizers from entering gliomas. Therefore, in order to maximize the sensitization efficiency of radiosensitizers, it is imperative to develop a delivery system that can not only cross the BBB around GBM and specifically target GBM, but also penetrate the central area of GBM.
[0004] Therefore, the present invention provides a nanomotor with a self-driving function, which uses the cell membrane on its surface to achieve cross-blood-brain barrier transport and brain glioma targeting. After reaching the tumor tissue, the built-in engine decomposes endogenous fuels such as glucose and hydrogen peroxide that are abundant in the tumor tissue, resulting in a high product concentration at the opening of the nanomotor, promoting the flow of the surrounding fluid, and reacting to the nanomotor itself, thereby achieving the self-driving movement of the nanomotor by self-diffusion phoresis. The self-propulsion of the nanomotor is used to promote diffusion and overcome convection, thereby achieving deep penetration of the tumor, delivering the radiosensitizer to the center of the tumor, and improving its radiosensitization effect. The nanomotor drug provided by the present invention not only has the function of delivering radiosensitizers, but also can be easily transformed into a delivery platform for loading clinical drugs, and has great clinical transformation potential in the field of tumor treatment. Summary of the invention
[0005] The technical problem to be solved by the present invention is to overcome the problem of weak diffusion and convection in solid tumors, and the difficulty of transporting drugs to the center of the tumor, and provide a method and platform for improving drug penetration, providing new ideas and means for tumor radiotherapy. The self-propulsion of the hollow nanomotor with an opening structure provided by the present invention does not require the assistance of external equipment. It can efficiently decompose endogenous glucose or hydrogen peroxide fuel by itself, resulting in a high product concentration at the opening, thereby driving the self-propulsion of nanomedicines, improving the diffusion ability and enhancing the penetration ability under the adverse pressure gradient, and significantly improving its penetration depth.
[0006] To achieve the above purpose, the present invention discloses the following technical contents: A hollow nanomotor with an opening structure, characterized in that it comprises a hollow nanoshell with an opening structure, a built-in catalytic engine and a cell membrane coated on the surface of the nanoshell; the surface of the hollow nanoshell with an opening structure contains only one opening for material exchange.
[0007] The hollow nanoshell with an opening structure is one of polydopamine, carbon, tannic acid, polystyrene, polylactic acid, polyε-caprolactone, polylactic acid-glycolic acid, silicon dioxide, titanium dioxide, and zinc oxide. The particle size of the hollow nanomotor with an opening structure is 50-1000 nm.
[0008] The hollow nanoshell with an opening structure is a hollow structure, and the functional molecules are loaded in the cavity; the functional molecules refer to small molecule drugs, such as temozolomide, doxorubicin, paclitaxel, oxaliplatin, fluorouracil, etc.
[0009] The built-in engine is at least one natural enzyme or nanozyme; the natural enzyme or nanozyme refers to catalase, superoxide dismutase, glucose oxidase, urease, lipase, DNA enzyme or ruthenium, rhodium, palladium, osmium, iridium, platinum, gold, silver, vanadium, iron, cobalt, nickel, copper, zinc, molybdenum nanoparticles. Glucose oxidase and platinum nanoparticles are preferred.
[0010] The cell membrane coated on the surface of the nanoshell is a cell membrane or a hybrid cell membrane, which is used to cross the blood-brain barrier or target tumor tissue; the cell membrane refers to the cell membrane extracted from animal or human cells; the hybrid cell membrane refers to two or more cells mixed together. Typical examples include mouse breast cancer cell membrane, macrophage membrane, neutrophil membrane, platelet membrane, red blood cell membrane, etc.
[0011] The present invention further discloses a method for preparing a hollow nanomotor with an opening structure, which is characterized by being carried out in the following steps: Step 1, preparing nanoparticles encapsulating natural enzymes or nanozymes in an aqueous solution; Step 2, dispersing the nanoparticles encapsulating the natural enzyme or nanozyme prepared in step 1 in a new coating solution, synthesizing the coated nanoparticles by a seed-mediated anisotropic growth method; and determining the size of the opening by controlling the reaction time; the coating solution refers to dopamine, tannic acid or styrene solution; the concentration is 0.1-10 mg / mL.
[0012] The seed-mediated anisotropic growth method refers to the coating starting from a point on the surface of the nanoparticle and gradually covering the entire surface; Step 3, placing the nanoparticles wrapped with the coating prepared in step 2 in an etching solution, and etching the nanoparticles to obtain a hollow nanoshell with an opening structure, wherein one or more natural enzymes or nanozymes are loaded inside the nanoshell; Step 4, co-incubating the motor-loaded nanoshell prepared in step 3 with the extracted broken cell membrane, and preparing a hollow nanomotor with an opening structure by ultrasound or co-extrusion; The present invention further discloses the use of a hollow nanomotor with an opening structure in the preparation of tumor therapeutic drugs. In particular, the application of the nanomotor in improving diffusion capacity and achieving transportation under adverse pressure gradient. And the application of the nanomotor in improving drug penetration capacity carrier. Experimental results show that the nanomotor with a hollow opening structure has self-driving ability, enhances the targeting and penetration of brain glioma, improves the effect of radiotherapy, and inhibits the growth of brain glioma.
[0013] The present invention is described in more detail as follows: The hollow nanomotor with an opening structure provided by the present invention is characterized in that it can be used as a drug carrier platform to load various clinical drugs, enhance the penetration ability of the drugs, and thus improve the therapeutic effect.
[0014] The invention discloses a hollow nanomotor with an opening structure, comprising a nanoshell with a hollow opening structure, a built-in catalytic engine and a cell membrane coated on the surface of the nanoshell; the surface of the nanoshell with a hollow opening structure contains only one opening for material exchange.
[0015] Furthermore, the hollow nanoshell material with an opening structure is one of polydopamine, carbon, tannic acid, polystyrene, polylactic acid, poly-ε-caprolactone, polylactic acid-glycolic acid, silicon dioxide, titanium dioxide, and zinc oxide.
[0016] Furthermore, the particle size of the hollow nanoshell with an opening structure is 50-1000 nm.
[0017] Preferably, the particle size of the hollow nanoshell with an opening structure is 100-500 nm.
[0018] Furthermore, the hollow nanoshell with an opening structure is a hollow structure.
[0019] Furthermore, when the nanoshell with a hollow structure having an opening adopts the hollow structure, the nanoshell without a hollow structure having an opening carries functional molecules.
[0020] Preferably, the functional material is one or more of natural drugs, semi-synthetic drugs, synthetic drugs, and genetic engineering drugs, typically temozolomide, doxorubicin, paclitaxel, oxaliplatin, fluorouracil, and the like.
[0021] Furthermore, the built-in engine is at least one natural enzyme or nanozyme.
[0022] Preferably, the natural enzyme is at least one of catalase, superoxide dismutase, glucose oxidase, urease, lipase, and DNA enzyme; the nanozyme is at least one of ruthenium, rhodium, palladium, osmium, iridium, platinum, gold, silver, vanadium, iron, cobalt, nickel, copper, zinc, and molybdenum nanoparticles.
[0023] Glucose oxidase and platinum nanoparticles are preferred.
[0024] The method for preparing the hollow nanomotor with an opening structure of the present invention comprises the following steps: Step 1: preparing nanoparticles encapsulating natural enzymes or nanozymes in an aqueous solution.
[0025] Step 2, dispersing the nanoparticles encapsulating the natural enzyme or nanozyme prepared in step 1 in a new coating solution, synthesizing the coating-wrapped nanoparticles by a seed-mediated anisotropic growth method; and determining the size of the opening by controlling the reaction time.
[0026] Step 3, placing the coating-wrapped nanoparticles prepared in step 2 in an etching solution, and etching the nanoparticles to obtain a hollow nanoshell with an opening structure, wherein one or more natural enzymes or nanozymes are loaded inside the nanoshell.
[0027] Step 4, co-incubating the motor-loaded nanoshell prepared in step 3 with the extracted broken cell membrane, and preparing a hollow nanomotor with an opening structure by ultrasound or co-extrusion.
[0028] Furthermore, in step 1, the nanoparticles are one of metal organic framework materials, silicon dioxide, polystyrene, calcium carbonate, and calcium phosphate.
[0029] In step 2, the seed-mediated anisotropic growth method refers to the coating growing from a point on the surface of the nanoparticle and gradually covering the entire surface.
[0030] Furthermore, in the step 2, the reaction time is 1-24 h.
[0031] Furthermore, in step 3, the etching solution is an acid solution or an alkaline solution.
[0032] Preferably, in the ultrasonic treatment step, the ultrasonic power is 20-1000 W and the ultrasonic time is 0.5-300 min.
[0033] The present invention also discloses the use of a hollow nanomotor with an opening structure for preparing a tumor treatment drug. Further, the tumor includes lung cancer, breast cancer, colorectal cancer, prostate cancer, sarcoma, glioma, neuroblastoma, hemangioma, lymphangioma, gastrointestinal stromal tumor, teratoma, Wilms tumor, testicular cancer, ovarian cancer, thyroid cancer, and thyroid adenoma.
[0034] Furthermore, when the hollow nanomotor with an opening structure is used to prepare traumatic injury drugs, the concentration used is 0.1-5000 μg / mL.
[0035] Furthermore, when the hollow nanomotor with an opening structure is used to prepare traumatic injury drugs, the method of use is at least one of microneedle, local injection, intravenous injection, and intratumoral injection.
[0036] The invention also discloses the application of a hollow nanomotor with an opening structure for improving diffusion capacity and realizing transportation under an adverse pressure gradient.
[0037] The invention also discloses the application of a hollow nanomotor with an opening structure as a carrier for improving drug penetration ability.
[0038] The beneficial effects of the present invention are: 1. It provides a new idea to enhance the diffusion capacity of drugs and improve their penetration capacity under adverse pressure gradient; it also provides a nanomotor with a hollow opening structure that can be used for trauma treatment; 2. The modular design can easily transform this self-driving platform into a delivery carrier that can carry various clinical drugs, helping the drugs reach deep tissues to exert their effects and improving the therapeutic effects of drugs.
[0039] 3. The preparation method is simple. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 is a transmission electron microscopy image of ZIF-8 nanoparticles encapsulating glucose oxidase and platinum nanoclusters in Example 1; Figure 2 Transmission electron microscope images and scanning electron microscope images of the hollow nanomotor with an opening structure; Figure 3 Dark field imaging and element scanning of the hollow nanomotor with an opening structure; Figure 4 is the diffusion coefficient of the nanomotor with a hollow opening structure in glucose and hydrogen peroxide aqueous solutions; Figure 5 The penetration depth simulation diagram of the hollow nanomotor with an opening structure in the reverse pressure gradient model; Figure 6 To test the retention capacity of hollow nanomotors with opening structures in GBM model mice; Figure 7 To test the effect of hollow nanomotors with opening structures combined with RT in treating GBM model mice. DETAILED DESCRIPTION
[0041] The present invention is described below by specific embodiments. Unless otherwise specified, the technical means used in the present invention are methods known to those skilled in the art. In addition, the embodiments should be understood to be illustrative rather than limiting the scope of the present invention, and the essence and scope of the present invention are limited only by the claims. For those skilled in the art, various changes or modifications to the material components and dosages in these embodiments, without departing from the essence and scope of the present invention, also belong to the protection scope of the present invention. The raw materials used in the present invention, such as dimethylimidazole, zinc nitrate, dopamine, sodium citrate buffer, glucose oxidase, platinum nanoclusters, etc., are all commercially available.
[0042] Example 1 (HM-GP@HPDA) A method for preparing a hollow nanomotor with an opening structure comprises the following steps: S1: Preparation of ZIF-8 nanoparticles encapsulating glucose oxidase and platinum nanoclusters: 5 mg of glucose oxidase and 32 μmol of platinum nanoclusters were added to 10 mL of deionized water, and then 1.66 g of 2-methylimidazole was added under continuous stirring. After 10 minutes, 104 mg of Zn(NO3)26H2O was added under vigorous stirring. The reaction lasted for 4 hours, and then centrifuged at 8000 rpm to obtain GP@ZIF-8.
[0043] S2: Coating Growth Under continuous stirring, 17.7 mL of anhydrous ethanol and 200 μL of NH3H2O were added to 40 mL of deionized water. After 10 minutes, 6 mg of GP@ZIF-8 obtained in the previous step was added to the solution and stirred for another 30 minutes. After that, 5 mL of dopamine solution (10 mg / mL) was added dropwise, and the solution gradually changed from colorless to black. After continuing the reaction for 24 hours, centrifuge at 8000 rpm to obtain GP@PDA.
[0044] S3: Core Etching The obtained unetched GP@PDA was redispersed in 2 mL of sodium citrate (0.04 mol / L):NaCl (0.02 mol / L) buffer (pH 5.0), allowed to stand for 12 h, and then centrifuged at 8000 rpm for 10 min to obtain GP@HPDA.
[0045] S4: Cell membrane wrapping 4 mg GP@HPDA was mixed with 2 mg 4T1 cell membrane and 2 mg RAW 264.7 cell membrane, and then sonicated (40 kHz / 80 W, 5 min). The mixture was then centrifuged at 5000 rpm for 10 min to obtain a hollow nanomotor with an opening structure.
[0046] The difference from Example 1 is that its surface is only coated with macrophage membrane.
[0047] Compared with the examples, comparative example 1 only uses the same nanoshell and cell membrane as in example 1, without the internal glucose oxidase and platinum nanoclusters. The specific preparation steps are as follows: First, add 1.66 g of 2-methylimidazole to 10 mL. After 10 minutes, add 104 mg of Zn(NO3)26H2O under vigorous stirring. The reaction lasts for 4 hours, and then centrifuges at 8000 rpm to obtain GP@ZIF-8. Under continuous stirring, add 17.7 mL of anhydrous ethanol and 200 μL of NH3H2O to 40 mL of deionized water. After 10 minutes, add 6 mg of GP@ZIF-8 obtained in the previous step to the solution and stir for another 30 minutes. After that, add 5 mL of dopamine solution (10 mg / mL) dropwise, and the solution gradually changes from colorless to black. After continuing the reaction for 24 hours, centrifuge at 8000 rpm to obtain GP@PDA. The obtained unetched GP@PDA was redispersed in 2 mL of sodium citrate (0.04 mol / L): NaCl (0.02 mol / L) buffer (pH 5.0), and after standing for 12 hours, centrifuged at 8000 rpm for 10 minutes to obtain GP@HPDA. 4 mg of GP@HPDA was mixed with 2 mg of 4T1 cell membrane and 2 mg of RAW 264.7 cell membrane, and then ultrasonicated (40 kHz / 80 W, 5 minutes). Then, the mixture was centrifuged at 5000 rpm for 10 minutes to obtain a hollow nanomotor with an opening structure that did not load glucose oxidase and platinum nanoclusters.
[0048] In order to test the beneficial effects of the present invention, the following application examples 1-4 are specially set up.
[0049] Motion performance test of hollow nanomotor with opening structure The prepared hollow nanomotors with opening structures were resuspended in PBS buffer (pH 7.4) to prepare a dispersion with a concentration of 1 mg / mL. 10 μL was added to 1 mL of 3 mM glucose / 300 μmol hydrogen peroxide mixed solution, and the apparent diffusion coefficient was measured using a dynamic light scattering (DLS) instrument. Figure 4 It can be seen that the hollow structure with openings has the highest apparent diffusion coefficient, proving that it has better diffusion ability in glucose / hydrogen peroxide solution.
[0050] Simulated permeation results of hollow nanomotors with openings under adverse pressure gradient The simulation was constructed using COMSOL Multiphiscs software. The creeping flow and chemical substance transport physics interfaces in the CFD module were used to simulate and construct the permeability distribution diagram of two different structures in the reverse pressure gradient field under microscopic 3D morphology. Figure 5It can be seen that the hollow nanomotor with an opening structure has a deeper distribution in the reverse pressure gradient field, proving that it has the ability to transport against the pressure gradient.
[0051] Testing the penetration ability of hollow nanomotors with openings in glioblastoma model mice In order to demonstrate that it can improve the penetration in TBI model mice, the following tests were performed: First, the GBM modeling method is as follows: GL261-luc cells are cultured and then harvested by centrifugation. The harvested cells are resuspended in DMEM to a cell suspension concentration of approximately 5 × 10 7 cells / mL. After anesthesia, the mouse was fixed using a stereotaxic device. The skin of the designated surgical area was disinfected and carefully cut with a blade. A tiny hole was made in the skull. Then, 2 μL of cell suspension (containing 1 × 10 5 GL261-luc cells) were injected into the right striatum of each mouse (stereotactic coordinate position, 1.0 mm anterior to bregma, 2.0 mm lateral to the midline, and 3.0 mm deep), and the whole procedure was completed within 5 min.
[0052] The specific detection indicators are as follows: To observe the distribution of HM-GP@HPDA in tumor tissue, DiO was used to label HM-GP@HPDA. 8 h after administration, the brain tissue was perfused with 4% paraformaldehyde solution, and then immersed in 4% paraformaldehyde solution overnight. The brain tissue was then cut longitudinally into 20 μm thick slices, and the penetration depth of HM-GP@HPDA was observed by laser confocal microscopy. Figure 6 As can be seen in the figure, the self-driven HM-GP@HPDA has a larger diffusion area, thus proving its higher penetration ability in brain tissue.
[0053] Testing the therapeutic effect of hollow nanomotors with opening structures in GBM model mice In order to evaluate the therapeutic effect of the hollow nanomotors with openings, magnetic resonance imaging (MRI) imaging experiments were used to test the size of glioblastoma in GBM model mice ( Figure 7 ). MRI is commonly used in clinical examinations of the occurrence and development of brain gliomas. The tumor area of mice treated with the hollow nanomotor with an opening structure plus gamma-ray irradiation was significantly smaller than that of the other three groups. This clearly shows that the hollow nanomotor with an opening structure improves the effectiveness of RT, thereby significantly inhibiting tumor growth.
[0054] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A nanomotor with a hollow opening structure, characterized in that: It includes a hollow nanoshell with an opening structure, a built-in catalytic engine, and a cell membrane coated on the surface of the nanoshell; The surface of the hollow nanoshell with an opening structure contains only one opening for material exchange.
2. The hollow nanomotor with an opening structure according to claim 1, characterized in that: The hollow nanoshell with an opening structure is one of polydopamine, carbon, tannic acid, polystyrene, polylactic acid, polyε-caprolactone, polylactic acid-glycolic acid, silicon dioxide, titanium dioxide and zinc oxide.
3. The hollow nanomotor with an opening structure according to claim 1, characterized in that: The particle size of the hollow nanomotor with an opening structure is 50-1000 nm.
4. The hollow nanomotor with an opening structure according to claim 1, characterized in that: The hollow nanoshell with an opening structure is a hollow structure, and the cavity thereof is loaded with functional molecules; the functional molecules refer to small molecule drugs.
5. The hollow nanomotor with an opening structure according to claim 1, characterized in that: The built-in engine is at least one natural enzyme or nanozyme; the natural enzyme or nanozyme refers to catalase, superoxide dismutase, glucose oxidase, urease, lipase, DNA enzyme or ruthenium, rhodium, palladium, osmium, iridium, platinum, gold, silver, vanadium, iron, cobalt, nickel, copper, zinc, molybdenum nanoparticles.
6. The hollow nanomotor with an opening structure according to claim 1, characterized in that: The cell membrane coated on the surface of the nanoshell is a cell membrane or a hybrid cell membrane, which is used to cross the blood-brain barrier or target tumor tissue; the cell membrane refers to the cell membrane extracted from animal or human cells; the hybrid cell membrane refers to two or more cell membranes physically mixed together.
7. A method for preparing a hollow nanomotor with an opening structure, characterized in that Proceed as follows: Step 1, preparing nanoparticles encapsulating natural enzymes or nanozymes in an aqueous solution; Step 2, dispersing the nanoparticles encapsulating the natural enzyme or nanozyme prepared in step 1 in a new coating solution, synthesizing the coated nanoparticles by a seed-mediated anisotropic growth method; and determining the size of the opening by controlling the reaction time; the coating solution refers to dopamine, tannic acid or styrene solution; The seed-mediated anisotropic growth method refers to the coating starting from a point on the surface of the nanoparticle and gradually covering the entire surface; Step 3, placing the nanoparticles wrapped with the coating prepared in step 2 in an etching solution, and etching the nanoparticles to obtain a hollow nanoshell with an opening structure, wherein one or more natural enzymes or nanozymes are loaded inside the nanoshell; Step 4, co-incubating the motor-loaded nanoshell prepared in step 3 with the extracted broken cell membrane, and preparing a hollow nanomotor with an opening structure by ultrasound or co-extrusion.
8. Use of the hollow nanomotor with an opening structure as described in any one of claims 1 to 6 in the preparation of tumor therapeutic drugs.
9. Use of the hollow nanomotor with an opening structure as described in any one of claims 1 to 6 for preparing a nanomotor with improved diffusion capacity and realizing transport under adverse pressure gradient.
10. Use of the hollow nanomotor with an opening structure as claimed in any one of claims 1 to 6 in preparing a carrier with improved drug penetration ability.
Citation Information
Cited By
Osmium-ruthenium nano-enzyme as well as preparation method and application thereof
CN120679525A
Osmium-ruthenium nanoscale enzyme, and preparation method and application thereof
CN120679525B
